

KaloBios Pharmaceuticals

Pharma & biotech

23 July 2013

Investment summary: Seeking a good life

Complete enrolment in a Phase II study of KB003 (anti-GM-CSF MAb) for severe asthma sets KaloBios on course for its first clinical proof-of-concept data in Q114 for its recombinant antibody technology. Conversely, recruitment into a Phase II trial of KB001-A (anti-PcrV MAb fragment) for *Pseudomonas* infections in cystic fibrosis (CF) patients has been slower than expected, delaying results by six months until Q414. Nevertheless, 2014 is shaping to be a pivotal year for KaloBios, and with a modest \$75m EV, the current share price could prove to be an attractive entry point.

Severe asthma study on track...

KaloBios has completed enrolment, ahead of schedule, into a [160-patient](#) Phase II study of KB003 in patients with asthma inadequately controlled by corticosteroids. Randomised 1:1, patients will receive 400mg IV antibody or saline (+ current medications) on weeks 0, 2, 4, 8, 12, 16, 20, with change in FEV₁ at week 24 the primary end point. Phase I/II data suggest that patients with airway reversibility ($\geq 12\%$ change in FEV₁ after beta agonist) respond better to anti-GM-CSF, and targeting GM-CSF has potential for both allergic and non-allergic severe asthma.

...while CF study slower than expected

Recruitment into the [180-patient](#) Phase II study of KB001-A has been slower than planned, partly due to other CF trials underway in the US. Top-line data, previously targeted for Q214, should now be available in Q414. Randomised 1:1, patients will receive 10 mg/kg IV antibody or saline on weeks 0, 2, 4, 8, 12, with time-to-need for antibiotic (ABX) treatment by week 16 the primary end point. KB001-A has anti-inflammatory and anti-infective properties by blocking the ability of *Pseudomonas aeruginosa* to secrete toxins that kill immune cells and reducing cytokine release. Sanofi is developing KB001-A for ventilator-associated pneumonia and has global opt-in rights to the antibody post-Phase II (18% royalties ex-US/50% US profits).

Blood cancer target adds third pipeline option

KB004 (anti-EphA3 MAb) has potential in haematologic malignancies. A [40-patient](#) dose-escalation Phase I study is ongoing (sixth dose level, 190mg, being tested), with expansion into a Phase II study in AML/MDS planned for Q313.

Valuation: \$75m EV could prove attractive

With \$77m in cash at end-Q113 (\$62m net IPO – 8.75m shares at \$8 – funds in February 2013), and \$10m debt (from \$15m MidCap Financial venture finance facility), KaloBios' \$75m EV seems modest given the significant pipeline potential.

Consensus estimates

Year End	Revenue (\$m)	PBT (\$m)	EPS (\$)	DPS (\$)	P/E (x)	Yield (%)
12/12	6.1	(23.5)	(11.2)	0.0	N/A	N/A
12/13e	0.1	(41.4)	(1.83)	0.0	N/A	N/A
12/14e	11.3	(35.5)	(1.26)	0.0	N/A	N/A

Source: Bloomberg

Price **\$5.87**
Market cap **\$142m**

Share price graph



Share details

Code	KBIO
Listing	NASDAQ
Sector	Pharma & biotech
Shares in issue	24.2m

Business description

KaloBios is a US biotechnology company developing monoclonal antibodies for severe respiratory diseases and cancer. KB003 (anti-GM-CSF MAb), KB001-A (anti-PcrV MAb fragment) and KB004 (anti-EphA3 MAb) are undergoing Phase I and II clinical studies.

Bull

- Maturing pipeline from novel antibody technology.
- Potential first-in-class candidates for novel targets.
- Strong balance sheet with additional funds available from MidCap and Sanofi.

Bear

- Pipeline candidates yet to achieve clinical proof-of-concept.
- Targeting competitive markets and established products.
- Financing required in 12-18 months; delay to CF study puts strain on existing cash reserve.

Analysts

Christian Glennie	+44 (0)20 3077 5727
Robin Davison	+44 (0)20 3077 5737

healthcare@edisongroup.com

EDISON QUICKVIEWS ARE NORMALLY ONE OFF PUBLICATIONS WITH NO COMMITMENT TO WRITING ANY FOLLOW UP. QUICKVIEW NOTES USE CONSENSUS EARNINGS ESTIMATES.

Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Berlin, Sydney and Wellington. Edison is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is not regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com.

DISCLAIMER

Copyright 2013 Edison Investment Research Limited. All rights reserved. This report has been prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Aus and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is not registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited ("FTSE") © FTSE [2013]. "FTSE®" is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE's express written consent.

Berlin +49 (0)30 2088 9525
Friedrichstrasse 95
10117 Berlin
Germany

London +44 (0)20 3077 5700
280 High Holborn
London, WC1V 7EE
United Kingdom

New York +1 646 653 7026
245 Park Avenue, 39th Floor
10167, New York
US

Sydney +61 (0)2 9258 1162
Level 33, Australia Square
264 George St, Sydney
NSW 2000, Australia

Wellington +64 (0)4 8948 555
Level 15, 171 Featherston St
Wellington 6011
New Zealand